Literature DB >> 18498876

Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.

Balraj Singh1, Kendra R Cook, Laura Vincent, Carol S Hall, Jacob A Berry, Asha S Multani, Anthony Lucci.   

Abstract

INTRODUCTION: Cyclooxygenase (COX2) expression in primary breast cancer correlates with a worse prognosis. We reported previously that COX2 expression in MCF10A breast epithelial cells of basal subtype induces genomic instability. To understand the role of COX2 in estrogen receptor-positive (non-basal) breast cancer, we transfected the MCF7 cell line with COX2 and analyzed its chromosomal profile, BCL2 protein expression, and resistance to doxorubicin. We also analyzed cell cultures grown as mammospheres to determine whether COX2 expression affects the cancer-initiating ("stem") cell phenotype in MCF7 cells.
METHODS: MCF7 Tet On cells (obtained from Clontech) were stably transfected with pTRE2pur-COX2 or pTRE2pur-COX2-GFP to produce COX2 or COX2-GFP protein, respectively. BCL2 protein was detected by Western blotting. Sensitivity of cells to drug treatment was analyzed by MTT assay. Groups were compared using Chi-Square test. We analyzed the genomic instability phenotype by chromosome analysis of control and COX2 transfected metaphase-arrested MCF7 cells after Giemsa staining. We assessed the tumorigenic potential of cells grown as mammospheres with a clonogenic assay.
RESULTS: Cytogenetic analysis of early passage COX2 transfected MCF7 cells demonstrated significant genomic instability as compared to parental MCF7 cells. COX2 overexpression was associated with a significant increase in chromosomal aberrations (chromatid breaks, chromosome fusions, C anaphase). COX2 transfected MCF7 cells produced a significantly higher level of the anti-apoptotic protein BCL2 than the parental cells. In a functional assay, we found that COX2 expression correlated with increased resistance to doxorubicin. In a complimentary approach to determine tumorigenic potential of cells, we found that COX2 increased the ability of MCF7 cells to grow as mammospheres in culture, which correlated with an increase in clonogenic efficiency.
CONCLUSIONS: We found that COX2 expression in MCF7 breast cancer cells induced genomic instability, BCL2 expression, and doxorubicin resistance, thus making them significantly more tumorigenic. This data suggests that COX-2 may be an important target for breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498876     DOI: 10.1016/j.jss.2008.02.026

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  26 in total

1.  ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression.

Authors:  Sun-Hee Kim; Yun-Yong Park; Sang-Wook Kim; Ju-Seog Lee; Dingzhi Wang; Raymond N DuBois
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 2.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

3.  Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis.

Authors:  Hiroshi Y Yamada; Yixin Yao; Xiaoxing Wang; Yuting Zhang; Ying Huang; Wei Dai; Chinthalapally V Rao
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

4.  Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Authors:  Giuliana Cássia Morrone Taromaru; Vilmar Marques DE Oliveira; Maria Antonieta Longo Galvão Silva; Wagner Ricardo Montor; Fabio Bagnoli; José Francisco Rinaldi; Tsutomu Aoki
Journal:  Oncol Lett       Date:  2011-12-21       Impact factor: 2.967

5.  Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.

Authors:  Hiroki Takahashi; Aihua Li; David W Dawson; Oscar Joe Hines; Howard A Reber; Guido Eibl
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

Review 6.  Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.

Authors:  Magis Mandapathil; Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2011-06-26       Impact factor: 4.388

7.  Embryonic expression of cyclooxygenase-2 causes malformations in axial skeleton.

Authors:  Minsub Shim; Julie Foley; Colleen Anna; Yuji Mishina; Thomas Eling
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

Review 8.  The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).

Authors:  T L Whiteside; M Mandapathil; P Schuler
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

9.  Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

Authors:  Anthony Lucci; Savitri Krishnamurthy; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; James Reuben; Kristine Broglio; Kailash Mosalpuria; Ashutosh Lodhi; Laura Vincent; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2008-07-29       Impact factor: 4.872

10.  Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis.

Authors:  Johanna R Reed; Ronald P Leon; Majken K Hall; Kathryn L Schwertfeger
Journal:  Breast Cancer Res       Date:  2009-04-24       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.